The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis

Katharina Staufer1,2, Mirko Dengler3, Heidemarie Huber3, Rodrig Marculescu4, Rudolf Stauber5, Carolin Lackner5, Hans-Peter Dienes7, Daniël Kivaranovic8, Christian Schachner2, Markus Zeitlinger9, Beatrix Wulkersdorfer9, Peter Rauch10, Gerhard Prager11, Michael Trauner2 and Wolfgang Mikulits*3

soluble Axl (sAxl) was recently shown to be strongly released into the blood during liver fibrogenesis and hepatocellular carcinoma suggesting sAxl as a biomarker of liver diseases. In this study we are the first to evaluate sAxl in human serum in comparison to Enhanced Liver Fibrosis (ELF) test and transient elastography (TE; Fibroscan) for its value to detect significant (F ≥ 2), advanced fibrosis (F ≥ 3), and cirrhosis (F4) in different liver disease etiologies and healthy controls. To properly determine the diagnostic accuracy of sAxl, a test cohort as well as a validation cohort was employed using liver biopsy as a reference method. Most notably, sAxl was confirmed to be an accurate biomarker of liver fibrosis and cirrhosis. Its accuracy was increased, if total serum albumin was added to build a sAxl/albumin ratio. Thereby an AUC of 0.763, 0.776, 0.826, and 0.832 was achieved corresponding to histological fibrosis stages F ≥ 2, F ≥ 3, F4 with liver biopsy as a reference method, and cirrhosis according to imaging techniques, respectively. With a cut-off of 1.29, a sensitivity, specificity, PPV, and NPV of 78.5%, 80.1%, 44%, 94.9% for the detection of cirrhosis was achieved. In comparison, ELF test and TE showed an AUC of 0.910, and 0.934, respectively, for the detection of cirrhosis. However, performance of TE was not possible in 14.4% of patients and both, ELF11 test and TE bear the disadvantage of high costs. In conclusion, the sAxl/albumin ratio is suggested as an accurate biomarker of liver fibrosis and cirrhosis. Due to its easy applicability and low costs it is suitable as screening parameter for significant to advanced liver fibrosis and cirrhosis, especially if TE is not available or not applicable.

Cell Death and Disease (2017) 8, e3135; doi:10.1038/cddis.2017.554; published online 26 October 2017
sAxl accurately detects advanced liver fibrosis

K Stauffer et al

Table 1 Patient characteristics

|                      | All patients (N = 392) | Test cohort (N = 307) | Validation cohort (N = 85) | P-value |
|----------------------|------------------------|-----------------------|---------------------------|---------|
| Age (y); median (IQR) | 50.8 (38.3;59.5)       | 50.4 (37.1;59.8)      | 52.0 (43.0;58.5)          | 0.207   |
| Male sex; % (n)      | 55.0 (216)             | 56.7 (174)            | 49.4 (42)                 | 0.233   |
| BMI; median (IQR)    | 26.5 (23.7;31.3)       | 26.6 (23.7;33.3)      | 26.0 (23.5;28.5)          | 0.074   |

Liver disease etiology; % (n)

| Liver disease etiology | All patients (N = 392) | Test cohort (N = 307) | Validation cohort (N = 85) | P-value |
|------------------------|------------------------|-----------------------|---------------------------|---------|
| NAFLD                  | 43.6 (171)             | 45.3 (139)            | 37.6 (32)                 | 0.040   |
| Viral hepatitis        | 21.9 (86)              | 15.6 (48)             | 44.7 (38)                 | <0.001  |
| AIH/CLD/Overlap        | 18.1 (71)              | 19.2 (59)             | 14.1 (12)                 | 0.141   |
| PBC/PSC               | 8.6 (34)               | 9.8 (30)              | 4.7 (4)                   | 0.349   |
| AIH/Overlap            | 9.4 (37)               | 9.4 (29)              | 9.4 (8)                   | 1.000   |
| DILI                   | 2.0 (8)                | 2.0 (6)               | 2.4 (2)                   | 1.000   |
| ALD                   | 4.1 (16)               | 5.2 (16)              | 0.0 (0)                   | 0.016   |
| Cryptogenic            | 2.3 (9)                | 2.6 (8)               | 1.2 (1)                   | 0.692   |
| Healthy controls       | 7.9 (31)               | 10.1 (31)             | 0.0 (0)                   | n.d.    |

Cirrhosis according to imaging; % (n)

| Cirrhosis according to imaging | All patients (N = 392) | Test cohort (N = 307) | Validation cohort (N = 85) | P-value |
|-------------------------------|------------------------|-----------------------|---------------------------|---------|
| US only                       | 16.6 (65)              | 16.9 (52)             | 15.3 (13)                 | 0.718   |
| US + CT                       | 63.1 (41)              | 53.8 (28)             | 100 (13)                  | n.d.    |
| US + MRI                      | 15.4 (10)              | 19.0 (10)             | 0.0 (0)                   | n.d.    |
| US + CT + MRI                | 13.8 (9)               | 17.3 (9)              | 0.0 (0)                   | n.d.    |
| Liver biopsy; % (n)           | 79.3 (311)             | 73.6 (226)            | 100 (85)                  | n.d.    |
| sAxl; % (n)                   | 100 (392)              | 100 (307)             | 100 (85)                  | n.d.    |
| ELF test; % (n)               | 84.7 (332)             | 83.4 (256)            | 89.4 (76)                 | n.d.    |
| Fibroscan; % (n)              | 33.4 (131)             | 21.2 (65)             | 77.6 (66)                 | n.d.    |

Histopathological results were available in 311 of 392 patients

Table 2a Fibrosis grades based on liver biopsy

| Fibrosis stage; % (n) | All patients (N = 311/392) | Test cohort (N = 226/307) | Validation cohort (N = 85/85) | P-value |
|-----------------------|-----------------------------|---------------------------|-------------------------------|---------|
| 0                     | 21.9 (68)                   | 20.4 (46)                 | 25.9 (22)                     | 0.155   |
| 1                     | 26.7 (83)                   | 26.5 (60)                 | 27.1 (23)                     | 0.987   |
| 2                     | 20.9 (65)                   | 21.7 (49)                 | 18.6 (16)                     | 0.517   |
| 3                     | 10.3 (32)                   | 9.3 (21)                  | 12.9 (11)                     | 0.379   |
| 4                     | 20.3 (63)                   | 22.1 (50)                 | 15.3 (13)                     | 0.155   |

Liver biopsy was available in 311 of 392 patients

Table 2b Distribution of fibrosis grades stratified according to liver disease etiology (n = 311)

| Liver disease etiology | F0-1 | F2 | F3 | F4 | P-value |
|------------------------|------|----|----|----|---------|
| NAFLD                  | 62.0 (93) | 13.3 (20) | 11.3 (17) | 13.3 (20) |         |
| Viral hepatitis        | 36.0 (31) | 26.7 (23) | 12.8 (11) | 24.4 (21) |         |
| AIH/CLD/Overlap        | 18.6 (8)  | 46.5 (20) | 9.3 (4)   | 25.6 (11) |         |
| DILI                   | 87.5 (7)  | 12.5 (1)  | 0.0 (0)   | 0.0 (0)   |         |
| ALD                   | 0.0 (0)    | 10.0 (1)  | 0.0 (0)   | 90.0 (9)  |         |
| Cryptogenic            | 77.8 (7)  | 0.0 (0)   | 0.0 (0)   | 22.2 (2)  |         |

determination of F4 as compared to healthy controls. In the present study, we re-evaluated sAxl as a biomarker of liver fibrosis in comparison to ELF™ test and TE using liver biopsy as a reference method in a test and a validation cohort.

Results

Study population. In total, 392 (median age: 50.8y; male sex: 55%) patients were included. Of these, 361 patients showed chronic liver diseases, i.e. NAFLD, viral hepatitis (either chronic hepatitis B or C), autoimmune hepatitis (AIH), cholestatic liver disease (CLD), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), or overlap syndrome, ALD, drug-induced liver injury (DILI), and cryptogenic cirrhosis (Table 1). The test cohort, which consisted of 276 patients with chronic liver disease and 31 healthy controls (Medical University of Vienna), was compared to a validation cohort (Medical University of Graz) of 85 patients. Both cohorts did not significantly differ in terms of age, sex, and BMI distribution. None of the patients suffered from significant heart failure. In 4.1% of patients (15/361), chronic kidney disease (CKD) was present. None of the patients had advanced stages of CKD (4 or 5). Detailed patient characteristics are displayed in Table 1.

Histopathological results were available in 311 of 392 study participants. F2, F3 and F4 were present in 20.9% (n = 65), 10.3% (n = 32) and 20.3% (n = 63) of patients, respectively (Table 2a). According to imaging techniques, cirrhosis was present in 16.6% (n = 65) of patients (Table 1) (confirmed by liver biopsy in 63/65, no liver biopsy available in 2/65, no cirrhosis present in 327 patients). The distribution of fibrosis grades among the different liver disease etiologies, as determined by liver biopsy, is given in Table 2b. Further, all results of liver function tests are displayed in Table 2c.

sAxl levels depend on stage of liver fibrosis. sAxl levels according to liver disease etiology are presented in Table 3. Notably, sAxl levels in patients with AIH/CLD were significantly higher in the validation cohort. This was explained by...

Abbreviations: AIH, autoimmune hepatitis; ALD, alcoholic liver disease; CT, computed tomography; CLD, cholestatic liver disease; DILI, drug-induced liver injury; IQR, interquartile range; MRI, magnetic resonance imaging; n.d., not determined; NAFLD, non-alcoholic fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; US, ultrasound
significantly higher sAxl levels found in patients with PBC which was caused by a selection bias due to small sample size since only 4 patients of the validation cohort were compared to 13 patients of the test cohort. Overall sAxl levels increased according to the stage of fibrosis (Figure 1). sAxl levels were significantly higher in patients with F4 as compared to F0 to F3 (median sAxl: 71.6, IQR [53.9; 94.7] versus 43.4, IQR [35.5; 55.7]), as well as in patients with cirrhosis according to imaging compared to patients without cirrhosis as well as healthy controls (median sAxl: 72.06, IQR [54.06; 9.01] versus 43.3, IQR [35.85; 55.5]) versus 40.2 IQR [34.2; 48.0]) (Figure 1). Together, these data reveal that sAxl levels do not significantly change at early stages of hepatic fibrosis (F0-F3) whereas sAxl is highly elevated in liver cirrhosis (F4) compared to advanced fibrosis (F3).

Accuracy of sAxl to predict advanced liver fibrosis increases if combined with albumin. The AUC for the detection of F ≥ 2, F ≥ 3, and F4 compared to patients, and cirrhosis was 0.737, 0.749, 0.801, and 0.807, respectively (Table 4). Calculating a sAxl/albumin ratio increased the AUC to 0.763, 0.776, 0.826, and 0.831, respectively (Table 4, Supplementary Figure 1). sAxl/albumin ratios

| Table 2c | Laboratory parameters of patients with chronic liver diseases |
|-----------|---------------------------------------------------------------|
| Laboratory parameter | All patients | Test cohort | Validation cohort | P-value |
| | n=360/392 | n=275/307 | n=85/85 |
| AST (U/ml) median (IQR) | 42.5 (29.0;68.0) | 39.0 (27.0;64.0) | 53.0 (34.0;75.0) | 0.004 |
| ALT (U/ml); median (IQR) | 52.0 (33.0;93.5) | 50.5 (31.0;91.0) | 59.0 (40.0;115.5) | 0.057 |
| GGT (U/ml); median (IQR) | 80.0 (38.0;186.0) | 80.0 (37.0;208.0) | 84.0 (45.5;166.0) | 0.817 |
| Albumin (mg/dl); median (IQR) | 44.0 (41.0; 46.4) | 43.5 (39.9;46.3) | 45.0 (43.0;47.0) | 0.016 |
| Total bilirubin (mg/dl); median (IQR) | 0.7 (0.5;1.1) | 0.7 (0.5;1.1) | 0.64 (0.46;0.86) | 0.033 |
| Platelet count (G/L); median (IQR) | 221.5 (180.0;276.8) | 224.0 (181.0;285.0) | 212.0 (172.0;250.5) | 0.106 |
| MELD score; median (IQR) | 7.2 (6.4;8.5) | 7.5 (6.4;8.5) | 6.9 (6.4;7.8) | 0.049 |

| Table 3 | Results of non-invasive fibrosis assessment |
|-----------|---------------------------------------------|
| | All patients | Test cohort | Validation cohort | P-value |
| | n=392 | n=307 | n=85 |
| sAxl level (ng/ml); median (IQR) | Liver disease, n=361 | 45.7 (37.2;60.8) | 44.0 (36.1;59.1) | 53.0 (42.3;70.1) | 0.002 |
| | Liver disease, n=361 | 45.7 (37.2;60.8) | 44.0 (36.1;59.1) | 53.0 (42.3;70.1) | 0.002 |
| | NAFLD | 41.2 (33.8;52.8) | 40.7 (33.0;50.8) | 43.7 (36.4;57.5) | 0.076 |
| | Viral hepatitis | 56.6 (43.3;71.7) | 56.5 (43.0;77.3) | 57.3 (43.4;70.8) | 0.945 |
| | AIH/CLD/Overlap | 45.8 (37.6;70.2) | 43.7 (36.2;60.3) | 77.4 (51.9;83.0) | 0.001 |
| | DILI | 47.9 (34.5;75.4) | 62.2 (38.3;103.0) | n.d. | n.d. |
| | ALD | 63.5 (47.4;92.1) | 63.5 (47.4;92.1) | n.d. | n.d. |
| | Cryptogenic | 51.2 (38.7;67.2) | 50.1 (38.1;62.7) | n.d. | n.d. |
| sAxl/albumin; median (IQR) | Liver disease, n=361 | 0.82 (0.75;1.14) | 1.00 (0.80;1.39) | 1.21 (0.89;1.56) | 0.004 |
| | NAFLD | 0.92 (0.75;1.14) | 0.92 (0.75;1.13) | 0.93 (0.80;1.32) | 0.322 |
| | Viral hepatitis | 1.29 (0.97;1.69) | 1.32 (0.96;1.94) | 1.28 (0.98;1.58) | 0.537 |
| | AIH/CLD/Overlap | 1.07 (0.86;1.56) | 0.99 (0.84;1.40) | 1.94 (1.20;2.46) | 0.002 |
| | DILI | 1.16 (0.78;1.78) | 1.50 (0.86;2.63) | n.d. | n.d. |
| | ALD | 1.72 (1.07;2.59) | 1.72 (1.07;2.59) | n.d. | n.d. |
| | Cryptogenic | 1.11 (0.86;1.70) | 1.08 (0.85;1.68) | n.d. | n.d. |
| ELFTM test (ng/ml); median (IQR) | Liver disease, n=305 | 9.0 (8.3;10.1) | 9.2 (8.4;10.5) | 8.7 (8.1;9.5) | 0.012 |
| | NAFLD, n=162 | 8.7 (8.1;9.5) | 8.8 (8.2;9.7) | 8.3 (7.9;9.0) | 0.003 |
| | Viral hepatitis, n=66 | 9.3 (8.6;10.3) | 9.9 (8.8;11.0) | 9.0 (8.6;9.8) | 0.033 |
| | AIH/CLD/Overlap, n=62 | 9.4 (8.3;10.8) | 9.4 (8.3;10.7) | 9.0 (8.3;11.6) | 0.781 |
| | DILI | 1.16 (0.78;1.78) | 1.50 (0.86;2.63) | n.d. | n.d. |
| | ALD | 1.72 (1.07;2.59) | 1.72 (1.07;2.59) | n.d. | n.d. |
| | Cryptogenic | 1.11 (0.86;1.70) | 1.08 (0.85;1.68) | n.d. | n.d. |
| Fibroscan (kPa); median (IQR) | Liver disease, n=313 | 7.9 (5.8;11.8) | 8.0 (6.0;11.6) | 7.8 (5.4;11.8) | 0.715 |
| | NAFLD, n=75 | 8.1 (6.0;10.0) | 8.4 (6.2;11.4) | 7.6 (5.8;10.5) | 0.841 |
| | Viral hepatitis, n=33 | 8.8 (4.9;12.6) | n.d. | n.d. | 8.4 (9.1;12.5) | 0.328 |
| | AIH/CLD/Overlap, n=18 | 7.2 (5.9;10.1) | 6.4 (5.8;10.4) | 7.8 (6.9;10.0) | 0.328 |
| | DILI | n.d. | n.d. | n.d. | n.d. |
| | ALD | n.d. | n.d. | n.d. | n.d. |
| | Cryptogenic | n.d. | n.d. | n.d. | n.d. |
| | Healthy controls, n=0 | n.d. | n.d. | n.d. | n.d. |

Results of non-invasive fibrosis markers were compared by Mann Whitney U – test. n.d., not determined
Figure 1  sAxl serum levels according to stage of fibrosis as well as presence of liver cirrhosis based on imaging methods. Statistical significant differences are expressed as asterisks; ***P<0.001

sAxl/albumin ratio has acceptable accuracy compared to ELF test and TE. ELF test and TE showed excellent diagnostic accuracy for the detection of liver fibrosis and cirrhosis. Data on their diagnostic performance are shown in Table 4 and Supplementary Figure 2. Yet, in terms of TE, 10.9% (n = 8/73) of the test cohort, and 16.4% (n = 14/85) of the validation cohort had to be excluded due to unreliable measurements. Thus, in total 131 of 153 measurements were available for statistical analysis (Table 1).

sAxl/albumin showed an acceptable accuracy for the detection of F ≥ 2, F ≥ 3, F4, and cirrhosis in comparison to ELF test (Figure 3, Table 4) as well as TE (Table 4). Spearman’s correlation coefficients of sAxl with sAxl/albumin ratio, ELF test, and TE were 0.969 (P < 0.001), 0.465 (P < 0.001), and 0.215 (P = 0.007), respectively. sAxl/albumin ratio correlated with ELF test and TE show a Spearman’s correlation coefficient of 0.526 (P < 0.001), and 0.240 (P = 0.003), respectively.

sAxl and sAxl/albumin ratio are independent of sex and BMI. sAxl and sAxl/albumin ratio were independent of sex (median sAxl [IQR]: male versus female: 46.1 [37.7; 58.1] versus 43.82 [35.48; 61.15], P = 0.518; median sAxl/albumin [IQR]: 1.0 [0.83; 1.32] versus 1.02 [0.80; 1.50], P = 0.683). Additionally, sAxl and sAxl/albumin ratio were independent of BMI category. In total, 35.7% (n = 140/392) of patients were normal weight (BMI < 25), 34.4% (n = 135/392) of patients were overweight (BMI ≥ 25 and BMI < 30), and 29.8% (n = 117/392) of patients fulfilled the WHO criteria of obesity (BMI ≥ 30).24 No significant differences were found between median sAxl [IQR] in normal weight, overweight and obese patients which was 45.0 ng/ml [37.9; 63.1], 47.1 ng/ml [38.4; 60.4], and 42.9 ng/ml [34.1; 55.1], respectively (P = 0.056). Median sAxl/albumin ratio [IQR] in normal weight, overweight and obese patients was 1.01 [0.84; 1.43], 1.08 [0.85; 1.42], and 0.97 [0.77; 1.28], respectively (P = 0.226).

Discussion

sAxl was recently identified to be an excellent biomarker for early HCC23,25 as well advanced fibrosis and liver cirrhosis.23 In the present study we aimed at investigating the diagnostic accuracy of sAxl as a biomarker for significant and advanced liver fibrosis in comparison to established non-invasive fibrosis markers such as ELF test and TE. The present study confirmed sAxl as an accurate biomarker of liver cirrhosis. Its diagnostic accuracy could be further increased by calculating a sAxl/albumin ratio achieving an AUC of 0.826 for the diagnosis of F4. At a cut-off of 1.29, a sensitivity of 77.8 and a specificity of 78.5 were reached. Notably, sAxl and sAxl/albumin ratio was independent of sex and BMI.

Axl is a member of the TAM (Tyro3, Axl, Mer) subfamily of receptor tyrosine kinases and so far known to be involved in cancer development and mediation of chemoresistance.26 Besides affecting cell survival, proliferation, migration and angiogenesis, Axl additionally plays a role in the clearance of apoptotic cells, platelet aggregation and the regulation of pro-inflammatory cytokine production.27,28 After proteolytic cleavage, the extracellular domain of Axl is released into the blood termed soluble Axl (sAxl).29 It has been shown to be elevated in serum or plasma in several diseases such as aortic aneurysm, heart failure, peripheral artery disease, CKD, systemic lupus erythematosus, rheumatoid arthritis, and preeclampsia.30–35 Furthermore, our group was able to show that sAxl is predominantly released by liver myofibroblasts that are generally associated with liver fibrosis progression.23 These findings were in line with a recent study showing that Axl is involved in liver fibrosis progression in a Axl knockout mouse model proving that Axl signalling via Growth arrest-specific 6 is required for hepatic stellate cell activation.20

This is the first study to compare the diagnostic accuracy of sAxl as a non-invasive biomarker of liver fibrosis with ELF test and TE. The latter two are among the most intensively evaluated non-invasive tests for liver fibrosis and have been commercialized. The results of our study correspond well with previous reports on the diagnostic accuracy of ELF test and TE.2,6,8 However, both tests bear the disadvantage of high costs.19 Additionally, TE shows limitations in applicability since reliable results cannot be generated in up to 15.8% of patients mainly attributable to obesity, presence of ascites, or less operator experience.8,36,37 Therefore, in our cohort in total 14.4% of TE tests had to be excluded from analysis.

In contrast, sAxl is a stable serum marker that can easily be measured by enzyme-linked immunosassay (ELISA) at low costs.38 Recently, we reported a diagnostic accuracy with an AUC of 0.918 (cut-off 53.89 ng/ml) for the detection of F ≥ 3, and an AUC of 0.935 (cut-off 54.0 ng/ml) for the detection of F4 in 190 chronic liver disease patients compared to healthy controls.23 In our present work we included 360 patients with chronic liver diseases as well as 31 healthy controls and we focused on discriminating significant to advanced fibrosis or...
| Fibrosis/cirrhosis | AUC (95%CI) | Sensitivity (%) | Specificity (%) | PPV | NPV | Youden’s Index | Cut-off |
|--------------------|-------------|----------------|----------------|-----|-----|----------------|--------|
| **sAxl**           |             |                |                |     |     |                |        |
| All patients       |             |                |                |     |     |                |        |
| F ≥ 2              | 0.737       | 59.4           | 80.2           | 73.1| 68.6| 0.396          | 52.78  |
| F ≥ 3              | 0.749       | 70.5           | 74.0           | 64.5| 86.5| 0.445          | 52.78  |
| F4                 | 0.801       | 77.8           | 71.9           | 38.9| 93.4| 0.497          | 52.98  |
| Cirrhosis          | 0.807       | 78.5           | 72.8           | 36.4| 94.4| 0.512          | 52.98  |
| NAFLD              |             |                |                |     |     |                |        |
| F ≥ 2              | 0.692       | 49.1           | 83.9           | 65.1| 72.9| 0.368          | 52.78  |
| F ≥ 3              | 0.747       | 62.2           | 86.7           | 60.5| 87.5| 0.489          | 52.78  |
| F4                 | 0.788       | 70.0           | 83.1           | 38.9| 94.7| 0.531          | 52.97  |
| Cirrhosis          | 0.776       | 70.0           | 82.1           | 34.1| 95.4| 0.521          | 52.97  |
| Viral hepatitis    |             |                |                |     |     |                |        |
| F ≥ 2              | 0.697       | 69.1           | 67.7           | 79.2| 55.3| 0.368          | 52.78  |
| F ≥ 3              | 0.718       | 78.1           | 57.4           | 52.1| 81.6| 0.535          | 54.00  |
| F4                 | 0.797       | 71.4           | 80.0           | 53.6| 89.7| 0.514          | 65.32  |
| Cirrhosis          | 0.788       | 71.4           | 80.0           | 53.6| 89.7| 0.514          | 65.32  |
| AIH/CLD/Overlap    |             |                |                |     |     |                |        |
| F ≥ 2              | 0.754       | 60.0           | 87.5           | 33.3| 47.5| 0.475          | 52.22  |
| F ≥ 3              | 0.676       | 60.0           | 67.9           | 50.0| 76.0| 0.279          | 60.32  |
| F4                 | 0.696       | 72.7           | 68.8           | 44.4| 88.0| 0.415          | 60.32  |
| Cirrhosis          | 0.760       | 75.0           | 78.0           | 40.9| 93.9| 0.530          | 60.32  |
| **sAxl/albumin**   |             |                |                |     |     |                |        |
| All patients       |             |                |                |     |     |                |        |
| F ≥ 2              | 0.763       | 54.4           | 88.1           | 81.3| 68.3| 0.425          | 1.29   |
| F ≥ 3              | 0.776       | 65.3           | 81.0           | 53.1| 87.4| 0.463          | 1.29   |
| F4                 | 0.826       | 77.8           | 78.5           | 46.2| 93.9| 0.562          | 1.29   |
| Cirrhosis          | 0.831       | 78.5           | 79.5           | 44.0| 94.9| 0.580          | 1.29   |
| NAFLD              |             |                |                |     |     |                |        |
| F ≥ 2              | 0.712       | 61.4           | 78.5           | 63.6| 76.8| 0.399          | 1.03   |
| F ≥ 3              | 0.774       | 62.2           | 92.0           | 71.9| 88.1| 0.542          | 1.19   |
| F4                 | 0.798       | 65.0           | 92.3           | 56.5| 94.5| 0.573          | 1.36   |
| Cirrhosis          | 0.789       | 66.0           | 91.4           | 50.0| 95.2| 0.564          | 1.36   |
| Viral hepatitis    |             |                |                |     |     |                |        |
| F ≥ 2              | 0.736       | 54.5           | 87.1           | 82.2| 51.9| 0.416          | 1.42   |
| F ≥ 3              | 0.750       | 53.1           | 90.7           | 77.3| 76.6| 0.439          | 1.69   |
| F4                 | 0.823       | 71.4           | 89.2           | 68.2| 90.6| 0.607          | 1.69   |
| Cirrhosis          | 0.823       | 71.4           | 89.2           | 68.2| 90.6| 0.607          | 1.69   |
| AIH/CLD/Overlap    |             |                |                |     |     |                |        |
| F ≥ 2              | 0.750       | 60.0           | 87.5           | 95.5| 33.3| 0.475          | 1.22   |
| F ≥ 3              | 0.657       | 63.6           | 96.4           | 83.0| 73.0| 0.298          | 3.66   |
| F4                 | 0.739       | 63.6           | 75.0           | 46.7| 85.7| 0.386          | 1.60   |
| Cirrhosis          | 0.805       | 75.0           | 79.7           | 42.9| 94.0| 0.547          | 1.47   |
| **ELF™ test**      |             |                |                |     |     |                |        |
| All patients       |             |                |                |     |     |                |        |
| F ≥ 2              | 0.819       | 75.4           | 76.4           | 73.7| 77.9| 0.517          | 9.2    |
| F ≥ 3              | 0.858       | 72.0           | 83.7           | 64.3| 89.2| 0.557          | 9.9    |
| F4                 | 0.909       | 89.1           | 78.4           | 46.6| 97.4| 0.675          | 9.8    |
| Cirrhosis          | 0.899       | 87.5           | 78.9           | 42.4| 97.4| 0.664          | 9.8    |
| NAFLD              |             |                |                |     |     |                |        |
| F ≥ 2              | 0.831       | 77.4           | 80.7           | 70.7| 85.5| 0.580          | 9.2    |
| F ≥ 3              | 0.876       | 90.9           | 75.0           | 52.6| 96.4| 0.659          | 9.2    |
| F4                 | 0.929       | 93.8           | 84.8           | 44.1| 99.1| 0.785          | 9.7    |

Table 4: Accuracy of sAxl, sAxl/albumin ratio, ELF™ test and transient elastography (Fibroscan®) for the detection of significant fibrosis (≥ F2), advanced fibrosis (≥ F3), F4 and cirrhosis according to imaging.
### Table 4 (Continued)

| Fibrosis/cirrhosis                  | AUC (95%CI) | Sensitivity (%) | Specificity (%) | PPV   | NPV   | Youden’s Index | Cut-off |
|-------------------------------------|-------------|-----------------|-----------------|-------|-------|----------------|---------|
| Cirrhosis                           | 0.936       | 93.8            | 86.3            | 42.9  | 99.2  | 0.801          | 9.7     |
| **Viral hepatitis**                 |             |                 |                 |       |       |                |         |
| F ≥ 2                               | 0.763       | 82.9            | 64.0            | 79.1  | 69.6  | 0.469          | 8.9     |
| F ≥ 3                               | 0.792       | 56.5            | 90.7            | 76.5  | 79.6  | 0.472          | 10.2    |
| F4                                  | 0.813       | 100             | 47.2            | 31.7  | 100   | 0.472          | 9.0     |
| Cirrhosis                           | 0.813       | 100             | 47.2            | 31.7  | 100   | 0.472          | 9.0     |
| **AIH/CLD/Overlap**                 |             |                 |                 |       |       |                |         |
| F ≥ 2                               | 0.747       | 50.0            | 100             | 100   | 33.0  | 0.500          | 10.8    |
| F ≥ 3                               | 0.795       | 81.8            | 79.2            | 64.3  | 90.5  | 0.610          | 10.8    |
| F4                                  | 0.872       | 100             | 80.8            | 64.3  | 100   | 0.808          | 10.8    |
| Cirrhosis                           | 0.898       | 90.0            | 88.5            | 60.0  | 97.9  | 0.785          | 10.8    |
| **Fibroscan®**                      |             |                 |                 |       |       |                |         |
| All patients                        |             |                 |                 |       |       |                |         |
| F ≥ 2                               | 0.850       | 67.0            | 86.0            | 77.3  | 77.9  | 0.524          | 9.4     |
| F ≥ 3                               | 0.890       | 76.0            | 88.0            | 66.7  | 92.0  | 0.639          | 11.1    |
| F4                                  | 0.970       | 88.0            | 95.0            | 75.0  | 98.0  | 0.834          | 16.6    |
| Cirrhosis                           | 0.930       | 84.0            | 96.0            | 76.2  | 97.3  | 0.799          | 16.6    |
| **NAFLD**                           |             |                 |                 |       |       |                |         |
| F ≥ 2                               | 0.853       | 81.8            | 74.5            | 58.1  | 90.5  | 0.563          | 8.9     |
| F ≥ 3                               | 0.935       | 90.9            | 80.6            | 45.5  | 98.0  | 0.716          | 10.1    |
| F4                                  | 0.935       | 100             | 78.5            | 36.4  | 100   | 0.786          | 10.1    |
| Cirrhosis                           | 0.937       | 100             | 79.1            | 36.4  | 100   | 0.791          | 10.1    |
| **Viral hepatitis**                 |             |                 |                 |       |       |                |         |
| F ≥ 2                               | 0.760       | 85.0            | 100             | 100   | 81.2  | 0.850          | 8.9     |
| F ≥ 3                               | 0.887       | 92.3            | 75.0            | 70.6  | 93.8  | 0.673          | 8.8     |
| F4                                  | 1.000       | 100             | 100             | 100   | 100   | 1.000          | 18.8    |
| Cirrhosis                           | 1.000       | 100             | 100             | 100   | 100   | 1.000          | 18.8    |
| **AIH/CLD/Overlap**                 |             |                 |                 |       |       |                |         |
| F ≥ 2                               | n.d.        | n.d.            | n.d.            | n.d.  | n.d.  | n.d.           | n.d.    |
| F ≥ 3                               | n.d.        | n.d.            | n.d.            | n.d.  | n.d.  | n.d.           | n.d.    |
| F4                                  | n.d.        | n.d.            | n.d.            | n.d.  | n.d.  | n.d.           | n.d.    |
| Cirrhosis                           | 1.000       | 100             | 100             | 100   | 100   | 1.000          | 23.1    |

Abbreviation: n.d., not determined
sAxl thereby achieved an AUC of 0.801 (cut-off 52.98 ng/ml) in identifying patients with F4. Diagnostic accuracy was increased to an AUC of 0.826 (cut-off 1.29) for the detection of F4 (reference method liver biopsy), and an AUC of 0.832 (cut-off 1.29) for the detection of liver cirrhosis (reference method imaging) by adding total serum albumin to the model. Using the same cut-off of 1.29, the AUC for the detection of significant fibrosis (F ≥ 2), advanced fibrosis (F ≥ 3), and F4 was 0.763, 0.776, and 0.826, respectively. At the cut-off of 1.29, PPV and NPV for the detection of F4 were 46.2 and 93.9%, respectively, thereby reliably ruling out the presence of F4.

In this context, we have to consider that using liver biopsy as a reference method, although representing the gold standard, may automatically lead to an underestimation of non-invasive biomarkers (AUC < 0.900) which is mostly due to sampling error and associated false negative results. 39,40 Furthermore, liver disease etiology has been previously shown to be a major factor influencing the performance of

**Figure 2** sAxl/albumin serum levels, ELF™ serum levels and Fibroscan results stratified according to liver biopsy (a–c) as well as stratified according to the presence of cirrhosis based on imaging test results (d–f). Statistical significant differences are expressed as asterisks: ***P < 0.001
non-invasive fibrosis markers. Especially in cholestatic liver diseases, such as PBC and PSC, data on non-invasive fibrosis assessment are limited. Additionally, classical histologic scoring systems such as those according to Ludwig, fibrosis may be only partly addressed through stages 3 and 4 (ref. 42,43). In our study sAxl/albumin ratio showed inconsistent cut-off levels within the cohort of AIH/CLD/Overlap patients with a cut-off of 3.66 for ≥ F3, but a cut-off of 1.6 for the diagnosis of F4 maybe reflecting a bias of sample size since only 4 patients in this group were classified F3 in liver histology.

Study limitations include a possible underestimation of liver fibrosis as assessed by liver histology in CLD patients, and data on ELF™ test and TE in this patient cohort is limited. Consecutively, the accuracy calculation of sAxl or sAxl/albumin might be confounded translating into underdiagnosis of significant fibrosis. Moreover, our findings cannot be uncritically translated to patients with DILI, ALD or cryptogenic liver disease due to low patient numbers in these groups.

Heart failure was excluded by the assessment of medical history and physical examination, but echocardiography was not routinely performed in all patients to exclude clinically inevitable or unknown heart failure. Therefore, sAxl levels might be increased due to unknown heart failure leading to false positive results in some patients. As CKD was reported to correlate with increased sAxl in plasma, we cannot exclude enhanced levels of sAxl due to mild CKD (stages 1-3) in 4.1% of our patients (15/361). However, median sAxl levels were lower in our patients with CKD than in patients without (48.09 versus 93.98 ng/ml). Neither the study by Batlle et al showing increased sAxl levels in heart failure, nor the study by Lee and colleagues reporting elevated sAxl levels in patients with CKD excluded liver diseases in their study cohorts. Further studies are warranted to investigate the true influence of heart failure and CKD on sAxl levels in liver disease patients.

In conclusion, sAxl/albumin ratio is an accurate marker of advanced liver fibrosis and cirrhosis in NAFLD and viral
hepatitis. Due to its easy applicability and low costs it is suitable as screening parameter for significant to advanced liver fibrosis and cirrhosis, especially in case if TE is not available or not applicable. The diagnostic accuracy of sAxl in AIH and cholestatic liver diseases should be confirmed in different patient cohorts.

Materials and Methods

Study population. Consecutive male and female patients with chronic liver disease as well as healthy volunteers were prospectively included in this study. Liver cirrhosis was either diagnosed by liver biopsy, liver imaging, i.e. ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI), or both biopsy and imaging. Liver biopsy was evaluated by two independent pathologists (CL and HPD). Liver fibrosis was graded either according to Kleiner,44 Ludwig45 or METAVIR46 as appropriate. Blood sampling including liver function tests was performed on the day of liver biopsy or, if biopsy was not executed, within one week of liver imaging. Immediately after each blood withdrawal, one sample of whole blood was centrifuged according to a standardized protocol and stored as serum aliquots at – 80 °C for later analysis of sAxl and ELF™ levels. In healthy volunteers liver disease was excluded by the thorough assessment of medical history, extensive laboratory tests as well as ultrasound. A test cohort was first investigated (Medical University of Vienna) followed by a validation cohort (Medical University of Graz) to confirm our findings. The medical history was thoroughly assessed in all patients and a complete physical examination was performed. Patients with acute infections, heart failure, immune-mediated diseases other than liver disease were not included in the study. Patients with CKD were categorized into CKD stages 1 to 5 (ref. 46). The study was conducted in accordance with the guidelines of the Declaration of Helsinki (1964, including current revisions) and GCP Guidelines after approval of the ethics committee of the Medical University of Vienna and Graz. All patients signed a written informed consent prior to study inclusion.

Commercialized liver fibrosis tests. ELF test was measured in serum on the ADVIA Centaur Immunoassay system according to the manufacturer’s protocol (Siemens Healthcare Diagnostics Inc., NY, USA). TE using Fibroscan® (Echosens, France) was performed in a standardized protocol and stored as serum aliquots at – 80 °C for later analysis of sAxl and ELF™ levels. In healthy volunteers liver disease was excluded by the thorough assessment of medical history, extensive laboratory tests as well as ultrasound. A test cohort was first investigated (Medical University of Vienna) followed by a validation cohort (Medical University of Graz) to confirm our findings. The medical history was thoroughly assessed in all patients and a complete physical examination was performed. Patients with acute infections, heart failure, immune-mediated diseases other than liver disease were not included in the study. Patients with CKD were categorized into CKD stages 1 to 5 (ref. 46). The study was conducted in accordance with the guidelines of the Declaration of Helsinki (1964, including current revisions) and GCP Guidelines after approval of the ethics committee of the Medical University of Vienna and Graz. All patients signed a written informed consent prior to study inclusion.

Enzyme-linked immunosorbent assay (ELISA). sAxl was measured in serum by solid phase sandwich ELISAs according to manufacturer’s protocol (R&D Systems, Minneapolis, USA) including modifications for optimization of the assay as published previously.23,38

Statistical analysis. Quantitative variables were expressed as median with interquartile range (IQR) and compared by Mann-Whitney U-tests. Qualitative variables were described using absolute and relative frequencies and were compared by Chi-Square- or Fisher’s exact tests, as appropriate. Comparison of more than two groups was done by the use of the Kruskal Wallis test. The Spearman’s correlation coefficient was used in order to assess correlations between all utilized non-invasive tests. The accuracy of sAxl was assessed by AUC for predicting (1) significant fibrosis (≥ F2), (2) advanced fibrosis (≥ F3), (3) F4, and (4) liver cirrhosis according to imaging as (A) a single marker and in combination with (C) serum albumin levels (mg/d; expressed as sAxl/albumin ratio). In order to identify optimal cut-off values, the Youden index was calculated.47 Additionally, sensitivity, specificity, PPV and NPV were computed. P-values < 0.05 were considered statistically significant. Statistical analysis was performed using IBM Statistics SPSS 24.0 (IBM Corp., Armonk, NY).

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. This work was supported by funds of the Österrei-

chische Nationalbank (Österreichische Nationalbank, Anniversary Fund, project number: 16673) (to WM).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

sAxl accurately detects advanced liver fibrosis

K Stauffer et al

1. European Association for the Study of the Liver. Electronic address: easloffice@easoffice.eu, EASL Recommendations on Treatment of Hepatitis C 2016. Journal of hepatology 2017; 66: 153–194.
2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–1402.
3. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado, EASL-ALEH Clinical Practice Guidelines: Non-Invasive tests for evaluation of liver fibrosis severity and progression. J Hepatol 2015; 63: 237–264.
4. Exekoul M, Hagstrom H, Nas P, Fredrickson M, Stal P, Kechagias S et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547–1554.
5. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review and meta-analysis of long-term follow-up studies. J Hepatol 2006; 44: 217–231.
6. Chen X, Wen H, Zhang X, Dong C, Lin H, Guo Y et al. Development of a Simple Noninvasive Model to Predict Significant Fibrosis in Patients with Chronic Hepatitis B: Combination of Ultrasound Elastography, Serum Biomarkers, and Individual Characteristics. Clin Transl Gastroenterol 2017; 8: e68.
7. Angulo P, Buganului E, Bjomsson ES, Charathacharoenwityha P, Mills PR, Barreira F et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782–789 e764.
8. Friedrich-Rust M, Rosenberg W, Parkes J, Hemmrich E, Zeuzem S, Sarrazzain C et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterology 2010; 10: 103.
9. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 450–460.
10. Adler M, Gubits B, Moreno C, Evard S, Verset G, Goldstein P et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index in noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology 2007; 47: 762–763 author reply 763.
11. Angulo P, Hui JMI, Marchesini G, Buganului E, George J, Farrell GC et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2005; 45: 846–854.
12. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2009; 42: 282–292.
13. Liang YF, Stum N, Faure P, Trome C, Marta A, Hilleret MN et al. Prospective evaluation of FibroTest(R), FibroMeter(R), and HepaScore(R) for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol 2014; 61: 28–34.
14. Ratzu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with chronic hepatitis C. BMC Gastroenterology 2009; 9: 6.
15. Mikolasevic I, Orlic L, Franjc N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan(R)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016; 22: 7236–7251.
16. Casamitjana C, Boursier J, de Leeding V, Lebigot J, Lapuyade B, Cales P et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology 2016; 63: 1817–1827.
17. Kim JH, Kim MN, Han KH, Kim SU. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int 2015; 35: 1103–1115.
18. Nahon P, Kettaneh A, Tengher-Barra I, Zoi M, de Leeding V, Douvin C et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49: 1062–1068.
19. Crossan C, Tschochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodrigue-Peralvarez M et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess 2015; 19: 1–409.
20. Barcena C, Stefavnic M, Tutusaus A, Joanas L, Menendez A, Garcia-Ruiz C et al. Gasa8/ Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. J Hepatol 2015; 63: 670–676.
21. Uehara S, Gotto K, Handa H, Nakay Y. Plasma levels of growth arrest specific protein (Gas6) and the soluble form of its tyrosine kinase receptor Axl (sAxl) in patients with hepatocellular carcinoma. J Cancer Ther 2013; 4: 632–639.
22. Uehara S, Fukuzawa Y, Matsuyama T, Gotto K. Role of Tyro3, Axl and Mer receptors and their ligands (Gas6 and Protein S) in patients with hepatocellular carcinoma. J Cancer Ther 2013; 4: 112–120.
23. Dengler M, Stauffer K, Huber H, Stauber R, Bantel H, Weiss KH et al. Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget 2017; 8: 46234–46248.
sAxl accurately detects advanced liver fibrosis

K Stauber et al

24. World Health Organization. Report of a WHO consultation on obesity. Obesity: preventing and managing the global epidemic. WHO 2000; 894: 1–253.

25. Reich P, Fang M, Starling D, Stauber K, Nenutil R, Muller P et al. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer 2015; 137: 385–394.

26. Vouri M, Hafizi S. TAM Receptor Tyrosine Kinases in Cancer Drug Resistance. Cancer Res 2017; 77: 275–278.

27. Hafizi S, Dahback B. Signaling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006; 17: 295–304.

28. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nature Rev Cancer 2014; 14: 769–795.

29. O'Brien JP, Fridell YW, Koski R, Vannum B, Liu ET. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem 1995; 270: 551–557.

30. Ekman C, Gottsater A, Lindblad B, Dahback B. Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia. Clin Biochem 2010; 43: 873–876.

31. Ekman C, Site DF, Gottsater A, Lindblad B, Dahback B. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. Clin Biochem 2010; 43: 110–114.

32. Ekman C, Linder A, Akesson P, Dahback B. Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit care 2010; 14: R158.

33. Liu X, Gong Y, Jia J, Bai Y, Gui S, Wang T et al. Plasma concentrations of sAxl are associated with severe preeclampsia. Clin Biochem 2014; 47: 173–176.

34. Battle M, Recarte-Pelz P, Roig E, Castel MA, Cardona M, Ferrero M et al. AXL receptor tyrosine kinase is increased in patients with heart failure. Int J Cardiol 2014; 173: 402–409.

35. Lee J, Hillard BA, Ulaa M, Yu D, Vangala C, Rao S et al. Monocyte and plasma expression of TAM ligand and receptor in renal failure: Links to unregulated immunity and chronic inflammation. Clin Immunol 2015; 158: 231–241.

36. Castera L, Foucher J, Bernard PH, Carvalho F, Affax D, Merrouche W et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828–835.

37. Woest GI, Wong WH, Chin AM, Yiu KK, Chu SH, Li MK et al. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 2011; 26: 300–305.

38. Dengler M, Huber H, Muller CJ, Zellmer A, Rauch P, Mikulits W. Accurate Determination of Soluble Axl by Enzyme-Linked Immunosorbent Assay. Assay Drug Dev Technol 2016; 14: 543–550.